Approved for treatment of cryopyrin‐associated periodic syndromes and systemic juvenile idiopathic arthritis;Rheumatoid arthritis phase II testing terminatedAtherosclerosis phase II completed. Here, NLRP3 is linked to rheumatoid arthritis.